![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PCNX3 |
Gene summary for PCNX3 |
![]() |
Gene information | Species | Human | Gene symbol | PCNX3 | Gene ID | 399909 |
Gene name | pecanex 3 | |
Gene Alias | PCNXL3 | |
Cytomap | 11q13.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H6A9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
399909 | PCNX3 | HCC1 | Human | Liver | HCC | 3.31e-02 | 2.09e+00 | 0.5336 |
399909 | PCNX3 | HCC2 | Human | Liver | HCC | 4.23e-05 | 2.38e+00 | 0.5341 |
399909 | PCNX3 | S014 | Human | Liver | HCC | 1.86e-09 | 3.11e-01 | 0.2254 |
399909 | PCNX3 | S015 | Human | Liver | HCC | 3.13e-06 | 3.32e-01 | 0.2375 |
399909 | PCNX3 | S016 | Human | Liver | HCC | 2.64e-10 | 2.88e-01 | 0.2243 |
399909 | PCNX3 | S027 | Human | Liver | HCC | 1.02e-04 | 3.53e-01 | 0.2446 |
399909 | PCNX3 | S028 | Human | Liver | HCC | 1.98e-25 | 6.35e-01 | 0.2503 |
399909 | PCNX3 | S029 | Human | Liver | HCC | 2.31e-16 | 5.42e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCNX3 | SNV | Missense_Mutation | c.371G>T | p.Arg124Leu | p.R124L | Q9H6A9 | protein_coding | deleterious(0.05) | probably_damaging(0.982) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
PCNX3 | SNV | Missense_Mutation | c.4001N>A | p.Gly1334Asp | p.G1334D | Q9H6A9 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PCNX3 | SNV | Missense_Mutation | c.310G>C | p.Glu104Gln | p.E104Q | Q9H6A9 | protein_coding | tolerated(0.37) | benign(0.019) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PCNX3 | SNV | Missense_Mutation | c.3385N>A | p.Ala1129Thr | p.A1129T | Q9H6A9 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PCNX3 | SNV | Missense_Mutation | c.418N>C | p.Val140Leu | p.V140L | Q9H6A9 | protein_coding | tolerated(0.58) | benign(0) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD | |
PCNX3 | SNV | Missense_Mutation | c.3952N>A | p.Val1318Met | p.V1318M | Q9H6A9 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-E2-A15G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
PCNX3 | SNV | Missense_Mutation | c.2241N>T | p.Gln747His | p.Q747H | Q9H6A9 | protein_coding | tolerated(0.09) | possibly_damaging(0.452) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PCNX3 | insertion | Nonsense_Mutation | novel | c.312_313insGCCAAAGTCTTCCTTTCTTGGATCGAGTGA | p.Glu104_Pro105insAlaLysValPheLeuSerTrpIleGluTer | p.E104_P105insAKVFLSWIE* | Q9H6A9 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | ||
PCNX3 | insertion | Frame_Shift_Ins | novel | c.256_257insTC | p.Asp86ValfsTer36 | p.D86Vfs*36 | Q9H6A9 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
PCNX3 | insertion | Frame_Shift_Ins | novel | c.257_258insTCTTTCCCTTCTTACTGTACATGGTGAGACG | p.Gln87LeufsTer84 | p.Q87Lfs*84 | Q9H6A9 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |